CIRM Funded Clinical Trials

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation


Disease Area:
Investigator:
CIRM Grant:
CLIN2-11371 (Closed)
Award Value:
$6,192,579.00
Trial Stage:
Phase 1|Phase 1/2
Trial Status:
Completed
Targeted Enrollment:
42
ClinicalTrials.gov ID:

Details:

Angiocrine Bioscience Inc. will use genetically engineered cells, derived from cord blood, to see if they can help alleviate or accelerate recovery from the toxic side effects of chemotherapy for people undergoing treatment for lymphoma and other aggressive cancers of the blood or lymph system.

Design:

First in human, Phase 1, multi-center trial

Goal:

Safety

News about this clinical trial:

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov